SCYNEXIS Inc（SCYX）の株式分析SCYXSCYNEXIS Inc

SCYNEXIS, Inc. is a biotechnology company focused on developing therapies to address severe rare diseases. The Company's SCY-770 is being developed for the treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD) and has been granted Orphan Drug designation. Its proprietary antifungal platform, fungerps, includes BREXAFEMME (ibrexafungerp tablets), which has been licensed to GSK, and SCY-247, which is in clinical stages of development. Its SCY-770 is a novel, highly selective, direct AMP-activated protein kinase (AMPK) activator for the treatment of ADPKD, a genetic cause of end-stage renal failure. Its SCY-770 is designed to address many of the underlying drivers of ADPKD by reducing cyst growth and disease progression. The United States Food and Drug Administration (FDA) has approved BREXAFEMME (ibrexafungerp tablets) for treatment of patients with vulvovaginal candidiasis (VVC) and for the reduction in the incidence of recurrent vulvovaginal candidiasis (rVVC). It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).

SCYNEXIS Inc (SCYX) is a good buy right now due to its recent financial turnaround, reporting a net income of $7.4 million for Q2 2026, which translates to $0.63 per share, a significant recovery from a net loss of $6.89 million in the same quarter last year. Additionally, the forward P/E ratio is at 3.72, indicating potential undervaluation compared to future earnings. However, the main risk is the recent net income loss of $21.3 million in Q1 2026, which highlights ongoing volatility in earnings.

7 analysts cover SCYX: 6 rate it Buy, 1 Hold and 0 Sell. The average price target is 3.50.